Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Treatment of echinococcosis

INTRODUCTION

Echinococcosis is caused by infection with the tapeworm echinococcus, which belongs to the family Taeniidae. Four species of echinococcus cause infection in humans. E. granulosus and E. multilocularis are the most common, causing cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. The two other species, E. vogeli and E. oligarthus, cause polycystic echinococcosis, but have been rarely associated with human infection. Two new species have been identified: Echinococcus shiquicus in small mammals from the Tibetan plateau and Echinococcus felidis in African lions; their transmission potential to humans is not known [1,2].

The treatment of cystic and alveolar echinococcal infection will be reviewed here. The clinical manifestations, diagnosis, epidemiology, and control of echinococcal infection are discussed separately. (See "Clinical manifestations and diagnosis of echinococcosis" and "Epidemiology and control of echinococcosis".)

CYSTIC ECHINOCOCCOSIS (E. GRANULOSUS)

Overview — Management options for cystic echinococcosis (CE) include surgery, percutaneous management, drug therapy, and observation [1]. Surgery has been the traditional approach for treatment of CE; subsequently, alternative approaches have been introduced and have replaced surgery as the treatment of choice in some cases [3].

In general, clinical approach depends on the World Health Organization (WHO) diagnostic classification (table 1 and image 1). Stage CE1 and CE3a cysts have a single compartment; such cysts that are <5 cm may be treated with albendazole alone [1]. In settings where albendazole treatment with follow-up monitoring is not feasible, definitive management with percutaneous treatment via PAIR (puncture, aspiration, injection, and reaspiration) is an acceptable alternative approach. Stage CE1 and CE3a cysts that are >5 cm may be treated with albendazole in combination with PAIR. In situations where albendazole treatment is not feasible, percutaneous treatment with PAIR (in the absence of adjunctive drug therapy) is an acceptable alternative approach [1]. Issues related to drug therapy are discussed below. (See 'Drug therapy' below.)

Stage CE2 and CE3b cysts have many compartments that require individual puncture; patients with such cysts commonly relapse after PAIR [4]. Therefore management of these cysts requires either modified catheterization technique (eg, non-PAIR percutaneous therapy) or surgery (with adjunctive drug therapy) [1]. The optimal choice between these approaches is uncertain and further study is needed.

                  

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2014. | This topic last updated: Mar 6, 2013.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Brunetti E, Kern P, Vuitton DA, Writing Panel for the WHO-IWGE. Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop 2010; 114:1.
  2. Menezes da Silva A. Hydatid cyst of the liver-criteria for the selection of appropriate treatment. Acta Trop 2003; 85:237.
  3. Dervenis C, Delis S, Avgerinos C, et al. Changing concepts in the management of liver hydatid disease. J Gastrointest Surg 2005; 9:869.
  4. Brunetti E, Garcia HH, Junghanss T, International CE Workshop in Lima, Peru, 2009. Cystic echinococcosis: chronic, complex, and still neglected. PLoS Negl Trop Dis 2011; 5:e1146.
  5. Khuroo MS, Dar MY, Yattoo GN, et al. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology 1993; 104:1452.
  6. Khuroo MS, Wani NA, Javid G, et al. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 1997; 337:881.
  7. Brunetti E, White AC Jr. Cestode infestations: hydatid disease and cysticercosis. Infect Dis Clin North Am 2012; 26:421.
  8. Nahmias J, Goldsmith R, Soibelman M, el-On J. Three- to 7-year follow-up after albendazole treatment of 68 patients with cystic echinococcosis (hydatid disease). Ann Trop Med Parasitol 1994; 88:295.
  9. Keshmiri M, Baharvahdat H, Fattahi SH, et al. A placebo controlled study of albendazole in the treatment of pulmonary echinococcosis. Eur Respir J 1999; 14:503.
  10. Todorov T, Mechkov G, Vutova K, et al. Factors influencing the response to chemotherapy in human cystic echinococcosis. Bull World Health Organ 1992; 70:347.
  11. Zlitni M, Ezzaouia K, Lebib H, et al. Hydatid cyst of bone: diagnosis and treatment. World J Surg 2001; 25:75.
  12. Singounas EG, Leventis AS, Sakas DE, et al. Successful treatment of intracerebral hydatid cysts with albendazole: case report and review of the literature. Neurosurgery 1992; 31:571.
  13. Todorov T, Vutova K, Petkov D, Balkanski G. Albendazole treatment of multiple cerebral hydatid cysts: case report. Trans R Soc Trop Med Hyg 1988; 82:150.
  14. Guidelines for treatment of cystic and alveolar echinococcosis in humans. WHO Informal Working Group on Echinococcosis. Bull World Health Organ 1996; 74:231.
  15. Anadol D, Ozçelik U, Kiper N, Göçmen A. Treatment of hydatid disease. Paediatr Drugs 2001; 3:123.
  16. Safioleas MC, Misiakos EP, Kouvaraki M, et al. Hydatid disease of the liver: a continuing surgical problem. Arch Surg 2006; 141:1101.
  17. Junghanss T, da Silva AM, Horton J, et al. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg 2008; 79:301.
  18. Bygott JM, Chiodini PL. Praziquantel: neglected drug? Ineffective treatment? Or therapeutic choice in cystic hydatid disease? Acta Trop 2009; 111:95.
  19. Cobo F, Yarnoz C, Sesma B, et al. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatisosis caused by Echinococcus granulosus. Trop Med Int Health 1998; 3:462.
  20. World Health Organization (WHO) Informal Working Group of Echinococcosis. Puncture, Aspiration, Injection, Re-Aspiration. An option for the treatment of cystic echinococcosis, p. 1–40. Document WHO/CDS/CSR/SPH/2001.6. Geneva, Switzerland: WHO; 2001. pp. 1–40.
  21. Moro P, Schantz PM. Echinococcosis: a review. Int J Infect Dis 2009; 13:125.
  22. Magistrelli P, Masetti R, Coppola R, et al. Surgical treatment of hydatid disease of the liver. A 20-year experience. Arch Surg 1991; 126:518.
  23. Behrns KE, van Heerden JA. Surgical management of hepatic hydatid disease. Mayo Clin Proc 1991; 66:1193.
  24. Di Matteo G, Bove A, Chiarini S, et al. Hepatic echinococcus disease: our experience over 22 years. Hepatogastroenterology 1996; 43:1562.
  25. Balik AA, Başoğlu M, Celebi F, et al. Surgical treatment of hydatid disease of the liver: review of 304 cases. Arch Surg 1999; 134:166.
  26. Safioleas M, Misiakos E, Manti C, et al. Diagnostic evaluation and surgical management of hydatid disease of the liver. World J Surg 1994; 18:859.
  27. Paksoy Y, Odev K, Sahin M, et al. Percutaneous treatment of liver hydatid cysts: comparison of direct injection of albendazole and hypertonic saline solution. AJR Am J Roentgenol 2005; 185:727.
  28. Dziri C, Haouet K, Fingerhut A, Zaouche A. Management of cystic echinococcosis complications and dissemination: where is the evidence? World J Surg 2009; 33:1266.
  29. Taylor DH, Morris DL. Combination chemotherapy is more effective in postspillage prophylaxis for hydatid disease than either albendazole or praziquantel alone. Br J Surg 1989; 76:954.
  30. Bickel A, Daud G, Urbach D, et al. Laparoscopic approach to hydatid liver cysts. Is it logical? Physical, experimental, and practical aspects. Surg Endosc 1998; 12:1073.
  31. Baskaran V, Patnaik PK. Feasibility and safety of laparoscopic management of hydatid disease of the liver. JSLS 2004; 8:359.
  32. Chowbey PK, Shah S, Khullar R, et al. Minimal access surgery for hydatid cyst disease: laparoscopic, thoracoscopic, and retroperitoneoscopic approach. J Laparoendosc Adv Surg Tech A 2003; 13:159.
  33. Ertem M, Karahasanoglu T, Yavuz N, Erguney S. Laparoscopically treated liver hydatid cysts. Arch Surg 2002; 137:1170.
  34. Seven R, Berber E, Mercan S, et al. Laparoscopic treatment of hepatic hydatid cysts. Surgery 2000; 128:36.
  35. Qian ZX. Thoracic hydatid cysts: a report of 842 cases treated over a thirty-year period. Ann Thorac Surg 1988; 46:342.
  36. Nasseri Moghaddam S, Abrishami A, Malekzadeh R. Percutaneous needle aspiration, injection, and reaspiration with or without benzimidazole coverage for uncomplicated hepatic hydatid cysts. Cochrane Database Syst Rev 2006; :CD003623.
  37. Neumayr A, Troia G, de Bernardis C, et al. Justified concern or exaggerated fear: the risk of anaphylaxis in percutaneous treatment of cystic echinococcosis-a systematic literature review. PLoS Negl Trop Dis 2011; 5:e1154.
  38. Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003; 37:1073.
  39. Salama H, Farid Abdel-Wahab M, Strickland GT. Diagnosis and treatment of hepatic hydatid cysts with the aid of echo-guided percutaneous cyst puncture. Clin Infect Dis 1995; 21:1372.
  40. Filice C, Brunetti E. Use of PAIR in human cystic echinococcosis. Acta Trop 1997; 64:95.
  41. Ustünsöz B, Akhan O, Kamiloğlu MA, et al. Percutaneous treatment of hydatid cysts of the liver: long-term results. AJR Am J Roentgenol 1999; 172:91.
  42. www.medicalweb.it/aumi/echinonet/ (Accessed on December 10, 2012).
  43. Men S, Hekimoğlu B, Yücesoy C, et al. Percutaneous treatment of hepatic hydatid cysts: an alternative to surgery. AJR Am J Roentgenol 1999; 172:83.
  44. Akhan O, Ozmen MN, Dinçer A, et al. Liver hydatid disease: long-term results of percutaneous treatment. Radiology 1996; 198:259.
  45. Yagci G, Ustunsoz B, Kaymakcioglu N, et al. Results of surgical, laparoscopic, and percutaneous treatment for hydatid disease of the liver: 10 years experience with 355 patients. World J Surg 2005; 29:1670.
  46. Filice C, Brunetti E. Echo-guided diagnosis and treatment of hepatic hydatid cysts. Clin Infect Dis 1997; 25:169.
  47. Stojkovic M, Zwahlen M, Teggi A, et al. Treatment response of cystic echinococcosis to benzimidazoles: a systematic review. PLoS Negl Trop Dis 2009; 3:e524.
  48. Aktan AO, Yalin R. Preoperative albendazole treatment for liver hydatid disease decreases the viability of the cyst. Eur J Gastroenterol Hepatol 1996; 8:877.
  49. Erzurumlu K, Hökelek M, Gönlüsen L, et al. The effect of albendazole on the prevention of secondary hydatidosis. Hepatogastroenterology 2000; 47:247.
  50. Arif SH, Wani NA, Zargar SA, et al. Albendazole as an adjuvant to the standard surgical management of hydatid cyst liver. Int J Surg 2008; 6:448.
  51. Gil-Grande LA, Rodriguez-Caabeiro F, Prieto JG, et al. Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease. Lancet 1993; 342:1269.
  52. Bildik N, Cevik A, Altintaş M, et al. Efficacy of preoperative albendazole use according to months in hydatid cyst of the liver. J Clin Gastroenterol 2007; 41:312.
  53. Manterola C, Mansilla JA, Fonseca F. Preoperative albendazole and scolices viability in patients with hepatic echinococcosis. World J Surg 2005; 29:750.
  54. Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in animals and humans: report of a workshop. Z Parasitenkd 1982; 67:5.
  55. El-On J. Benzimidazole treatment of cystic echinococcosis. Acta Trop 2003; 85:243.
  56. Horton RJ. Albendazole in treatment of human cystic echinococcosis: 12 years of experience. Acta Trop 1997; 64:79.
  57. Ammann RW, Eckert J. Cestodes. Echinococcus. Gastroenterol Clin North Am 1996; 25:655.
  58. Bezzi M, Teggi A, De Rosa F, et al. Abdominal hydatid disease: US findings during medical treatment. Radiology 1987; 162:91.
  59. Davis A, Dixon H, Pawlowski ZS. Multicentre clinical trials of benzimidazole-carbamates in human cystic echinococcosis (phase 2). Bull World Health Organ 1989; 67:503.
  60. Todorov T, Vutova K, Mechkov G, et al. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann Trop Med Parasitol 1992; 86:59.
  61. Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Agents Chemother 1993; 37:1679.
  62. Todorov T, Vutova K, Mechkov G, et al. Evaluation of response to chemotherapy of human cystic echinococcosis. Br J Radiol 1990; 63:523.
  63. Horton RJ. Chemotherapy of Echinococcus infection in man with albendazole. Trans R Soc Trop Med Hyg 1989; 83:97.
  64. Vutova K, Mechkov G, Vachkov P, et al. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 1999; 93:357.
  65. Todorov T, Vutova K, Petkov D, et al. Albendazole treatment of human cystic echinococcosis. Trans R Soc Trop Med Hyg 1988; 82:453.
  66. Franchi C, Di Vico B, Teggi A. Long-term evaluation of patients with hydatidosis treated with benzimidazole carbamates. Clin Infect Dis 1999; 29:304.
  67. Keshmiri M, Baharvahdat H, Fattahi SH, et al. Albendazole versus placebo in treatment of echinococcosis. Trans R Soc Trop Med Hyg 2001; 95:190.
  68. Morris DL, Dykes PW, Marriner S, et al. Albendazole--objective evidence of response in human hydatid disease. JAMA 1985; 253:2053.
  69. Mohamed AE, Yasawy MI, Al Karawi MA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology 1998; 45:1690.
  70. Wen H, New RR, Craig PS. Diagnosis and treatment of human hydatidosis. Br J Clin Pharmacol 1993; 35:565.
  71. Smego RA Jr, Sebanego P. Treatment options for hepatic cystic echinococcosis. Int J Infect Dis 2005; 9:69.
  72. McManus DP, Zhang W, Li J, Bartley PB. Echinococcosis. Lancet 2003; 362:1295.
  73. Yasawy MI, al Karawi MA, Mohamed AR. Combination of praziquantel and albendazole in the treatment of hydatid disease. Trop Med Parasitol 1993; 44:192.
  74. Yasawy MI, Alkarawi MA, Mohammed AR. Prospects in medical management of Echinococcus granulosus. Hepatogastroenterology 2001; 48:1467.
  75. Brunetti E, Junghanss T. Update on cystic hydatid disease. Curr Opin Infect Dis 2009; 22:497.
  76. Golemanov B, Grigorov N, Mitova R, et al. Efficacy and safety of PAIR for cystic echinococcosis: experience on a large series of patients from Bulgaria. Am J Trop Med Hyg 2011; 84:48.
  77. Sciarrino E, Virdone R, Lo Iacono O, et al. Ultrasound changes in abdominal echinococcosis treated with albendazole. J Clin Ultrasound 1991; 19:143.
  78. World Health Organization. Echinonet. Online version of Echinonews. 2000. Available at: www.medicalweb.it/aumi/echinonet/ (Accessed on March 08, 2005).
  79. Galitza Z, Bazarsky E, Sneier R, et al. Repeated treatment of cystic echinococcosis in patients with a long-term immunological response after successful surgical cyst removal. Trans R Soc Trop Med Hyg 2006; 100:126.
  80. Ben Nouir N, Nuñez S, Gianinazzi C, et al. Assessment of Echinococcus granulosus somatic protoscolex antigens for serological follow-up of young patients surgically treated for cystic echinococcosis. J Clin Microbiol 2008; 46:1631.
  81. Ben Nouir N, Gianinazzi C, Gorcii M, et al. Isolation and molecular characterization of recombinant Echinococcus granulosus P29 protein (recP29) and its assessment for the post-surgical serological follow-up of human cystic echinococcosis in young patients. Trans R Soc Trop Med Hyg 2009; 103:355.
  82. Zarzosa MP, Orduña Domingo A, Gutiérrez P, et al. Evaluation of six serological tests in diagnosis and postoperative control of pulmonary hydatid disease patients. Diagn Microbiol Infect Dis 1999; 35:255.
  83. Stettler M, Fink R, Walker M, et al. In vitro parasiticidal effect of Nitazoxanide against Echinococcus multilocularis metacestodes. Antimicrob Agents Chemother 2003; 47:467.
  84. Reuter S, Buck A, Grebe O, et al. Salvage treatment with amphotericin B in progressive human alveolar echinococcosis. Antimicrob Agents Chemother 2003; 47:3586.
  85. Kadry Z, Renner EC, Bachmann LM, et al. Evaluation of treatment and long-term follow-up in patients with hepatic alveolar echinococcosis. Br J Surg 2005; 92:1110.
  86. Torgerson PR, Schweiger A, Deplazes P, et al. Alveolar echinococcosis: from a deadly disease to a well-controlled infection. Relative survival and economic analysis in Switzerland over the last 35 years. J Hepatol 2008; 49:72.
  87. Ammann RW, Hirsbrunner R, Cotting J, et al. Recurrence rate after discontinuation of long-term mebendazole therapy in alveolar echinococcosis (preliminary results). Am J Trop Med Hyg 1990; 43:506.
  88. Wilson JF, Rausch RL, McMahon BJ, Schantz PM. Parasiticidal effect of chemotherapy in alveolar hydatid disease: review of experience with mebendazole and albendazole in Alaskan Eskimos. Clin Infect Dis 1992; 15:234.
  89. Wilson JF, Rausch RL, Wilson FR. Alveolar hydatid disease. Review of the surgical experience in 42 cases of active disease among Alaskan Eskimos. Ann Surg 1995; 221:315.
  90. Ammann RW, Fleiner-Hoffmann A, Grimm F, Eckert J. Long-term mebendazole therapy may be parasitocidal in alveolar echinococcosis. J Hepatol 1998; 29:994.
  91. Wilson JF, Rausch RL, McMahon BJ, et al. Albendazole therapy in alveolar hydatid disease: a report of favorable results in two patients after short-term therapy. Am J Trop Med Hyg 1987; 37:162.
  92. Ammann RW, Ilitsch N, Marincek B, Freiburghaus AU. Effect of chemotherapy on the larval mass and the long-term course of alveolar echinococcosis. Swiss Echinococcosis Study Group. Hepatology 1994; 19:735.
  93. Ishizu H, Uchino J, Sato N, et al. Effect of albendazole on recurrent and residual alveolar echinococcosis of the liver after surgery. Hepatology 1997; 25:528.
  94. Bresson-Hadni S, Koch S, Beurton I, et al. Primary disease recurrence after liver transplantation for alveolar echinococcosis: long-term evaluation in 15 patients. Hepatology 1999; 30:857.
  95. Bresson-Hadni S, Blagosklonov O, Knapp J, et al. Should possible recurrence of disease contraindicate liver transplantation in patients with end-stage alveolar echinococcosis? A 20-year follow-up study. Liver Transpl 2011; 17:855.